176 related articles for article (PubMed ID: 33899230)
1. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.
Chen Y; Huang F; Xuan L; Zhang Y; Fan Z; Xu N; Zhao K; Xu J; Liu H; Shi P; Wang Z; Sun J; Zheng W; Dai M; Liu Q
Int J Cancer; 2021 Sep; 149(5):1109-1120. PubMed ID: 33899230
[TBL] [Abstract][Full Text] [Related]
2. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.
Schroeder T; Wegener N; Lauseker M; Rautenberg C; Nachtkamp K; Schuler E; Kondakci M; Haas R; Germing U; Kobbe G
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1550-1559. PubMed ID: 30880268
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.
Zhang Y; Liu C; Zhang R; Shi Y; Li X; Yu J; Wan D; Xie X
Leuk Res; 2023 Jan; 124():106997. PubMed ID: 36502583
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Upfront Transplantation and Pretransplant Cytoreductive Therapy for Advanced Myelodysplastic Syndrome.
Wang H; Li Y; Xu Q; Zhou W; Yin C; Wang R; Wang M; Xu Y; Li Y; Yu L
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):631-640. PubMed ID: 34074612
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.
Oran B; Kongtim P; Popat U; de Lima M; Jabbour E; Lu X; Chen J; Rondon G; Kebriaei P; Ahmed S; Andersson B; Alousi A; Ciurea S; Shpall E; Champlin RE
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1618-25. PubMed ID: 24953017
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
Konuma T; Shimomura Y; Ozawa Y; Ueda Y; Uchida N; Onizuka M; Akiyama M; Mori T; Nakamae H; Ohno Y; Shiratori S; Onishi Y; Kanda Y; Fukuda T; Atsuta Y; Ishiyama K;
Hematol Oncol; 2019 Feb; 37(1):85-95. PubMed ID: 30370627
[TBL] [Abstract][Full Text] [Related]
9. Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.
Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Lee DG; Eom KS; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW; Min WS; Kim TG; Park CW; Kim YJ
Eur J Haematol; 2013 Feb; 90(2):111-20. PubMed ID: 23113470
[TBL] [Abstract][Full Text] [Related]
10. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
11. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
[TBL] [Abstract][Full Text] [Related]
12. [Impact of induced therapy before allogeneic hematopoietic stem-cell transplantation for higher-risk myelodysplastic syndrome: experience of single centre].
Zhou JY; He GS; Wu DP; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu ZZ; Ma X; Miao M; Xue SL; Wang Y
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3185-8. PubMed ID: 24405537
[TBL] [Abstract][Full Text] [Related]
13. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
[TBL] [Abstract][Full Text] [Related]
14. Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors.
Sun YQ; Xu LP; Liu KY; Zhang XH; Yan CH; Jin J; Huang XJ; Wang Y
Cancer Commun (Lond); 2021 Apr; 41(4):333-344. PubMed ID: 33566460
[TBL] [Abstract][Full Text] [Related]
15. [Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].
Wang QQ; Liu ZX; Zhao XL; Zhang GX; Yao JF; Zheng XH; Zhang LN; Shen YY; Zhao XL; He Y; Huang Y; Zhang RL; Wei JL; Ma QL; Pang AM; Yang DL; Zhai WH; Jiang EL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):132-137. PubMed ID: 32135630
[No Abstract] [Full Text] [Related]
16. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
17. [Clinic Outcome of Allogeneic Stem Cell Transplantation in 45 Patients with MDS].
Wang LJ; Liu MJ; Zhao XL; Ding J; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):502-9. PubMed ID: 27151019
[TBL] [Abstract][Full Text] [Related]
18. [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].
Lu CQ; Hou C; Wang P; Zhang LW; Fan Y; Wu DP; Xu Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):247-254. PubMed ID: 35405784
[No Abstract] [Full Text] [Related]
19. Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis.
Wang H; Li Y; Zhou W; Wang R; Li Y; Yu L
Leuk Res; 2021 Nov; 110():106645. PubMed ID: 34217112
[TBL] [Abstract][Full Text] [Related]
20. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
